Literature DB >> 27727222

BMS bets on targeting IL-8 to enhance cancer immunotherapies.

Elie Dolgin.   

Abstract

Entities:  

Year:  2016        PMID： 27727222     DOI： 10.1038/nbt1016-1006

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Bristol-Myers Squibb swallows last of antibody pioneers.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2009-09       Impact factor: 54.908

2.  Immune-checkpoint inhibitors march on, now in combinations.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2014-04       Impact factor: 54.908

3.  Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma.

Authors:  Suyun Huang; Lisa Mills; Badar Mian; Carmen Tellez; Marya McCarty; X-D Yang; Jean M Gudas; Menashe Bar-Eli
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

4.  Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB.

Authors:  Badar M Mian; Colin P N Dinney; Carlos E Bermejo; Paul Sweeney; Carmen Tellez; X D Yang; Jean M Gudas; David J McConkey; Menashe Bar-Eli
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

5.  CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Authors:  Colin W Steele; Saadia A Karim; Joshua D G Leach; Peter Bailey; Rosanna Upstill-Goddard; Loveena Rishi; Mona Foth; Sheila Bryson; Karen McDaid; Zena Wilson; Catherine Eberlein; Juliana B Candido; Mairi Clarke; Colin Nixon; John Connelly; Nigel Jamieson; C Ross Carter; Frances Balkwill; David K Chang; T R Jeffry Evans; Douglas Strathdee; Andrew V Biankin; Robert J B Nibbs; Simon T Barry; Owen J Sansom; Jennifer P Morton
Journal:  Cancer Cell       Date:  2016-06-02       Impact factor: 38.585
  5 in total
  2 in total

1.  Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study.

Authors:  Brian J Anderson; Carolyn S Calfee; Kathleen D Liu; John P Reilly; Kirsten N Kangelaris; Michael G S Shashaty; Aili L Lazaar; Andrew I Bayliffe; Robert J Gallop; Todd A Miano; Thomas G Dunn; Erik Johansson; Jason Abbott; Alejandra Jauregui; Thomas Deiss; Kathryn Vessel; Annika Belzer; Hanjing Zhuo; Michael A Matthay; Nuala J Meyer; Jason D Christie
Journal:  Crit Care       Date:  2019-12-09       Impact factor: 9.097

2.  Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1-IL-8 signaling-mediated epithelial-mesenchymal transition in lung adenocarcinoma.

Authors:  Xin Yang; Rui Chen; Yan Chen; You Zhou; Chen Wu; Qing Li; Jun Wu; Wen-Wei Hu; Wei-Qing Zhao; Wei Wei; Jun-Tao Shi; Mei Ji
Journal:  Cancer Sci       Date:  2022-02-22       Impact factor: 6.716
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.